Next Article in Journal
MiR-222 Targeted PUMA to Improve Sensitization of UM1 Cells to Cisplatin
Next Article in Special Issue
High Levels of KAP1 Expression Are Associated with Aggressive Clinical Features in Ovarian Cancer
Previous Article in Journal
TGF-β1 Protection against Aβ1–42-Induced Neuroinflammation and Neurodegeneration in Rats
Previous Article in Special Issue
Twist-1 Up-Regulation in Carcinoma Correlates to Poor Survival
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2014, 15(12), 22109-22127;

Battle Against Cancer: An Everlasting Saga of p53

1,* and 2,*
School of Continuing Studies, Tulane University, New Orleans, LA 70118, USA
Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong 999077, China
Authors to whom correspondence should be addressed.
Received: 20 September 2014 / Revised: 23 October 2014 / Accepted: 25 November 2014 / Published: 1 December 2014
(This article belongs to the Special Issue Advances in Molecular Oncology 2014)
Full-Text   |   PDF [755 KB, uploaded 1 December 2014]   |  


Cancer is one of the most life-threatening diseases characterized by uncontrolled growth and spread of malignant cells. The tumor suppressor p53 is the master regulator of tumor cell growth and proliferation. In response to various stress signals, p53 can be activated and transcriptionally induces a myriad of target genes, including both protein-encoding and non-coding genes, controlling cell cycle progression, DNA repair, senescence, apoptosis, autophagy and metabolism of tumor cells. However, around 50% of human cancers harbor mutant p53 and, in the majority of the remaining cancers, p53 is inactivated through multiple mechanisms. Herein, we review the recent progress in understanding the molecular basis of p53 signaling, particularly the newly identified ribosomal stress—p53 pathway, and the development of chemotherapeutics via activating wild-type p53 or restoring mutant p53 functions in cancer. A full understanding of p53 regulation will aid the development of effective cancer treatments. View Full-Text
Keywords: p53; mutant p53; MDM2; ribosomal stress; transcription; cancer chemotherapeutics p53; mutant p53; MDM2; ribosomal stress; transcription; cancer chemotherapeutics

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hao, Q.; Cho, W.C. Battle Against Cancer: An Everlasting Saga of p53. Int. J. Mol. Sci. 2014, 15, 22109-22127.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top